Ratings by Goldman Sachs (James Quigley)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/3/2026 | Novo Nordisk | NVO | Maintain | Neutral (N/A) |
|
Details | ||
| 3/2/2026 | Novo Nordisk | NVO | Downgrade | Neutral (Buy) |
37.62 (49.10) |
30.52% | Details | |
| 11/28/2025 | Novo Nordisk | NVO | Maintain | Buy (N/A) |
|
Details | ||
| 9/12/2025 | Novartis | NVS | Downgrade | Sell (Neutral) |
126.55 (155.74) |
23.07% | Details | |
| 3/21/2025 | Sanofi | SNY | New Coverage | Neutral (N/A) |
58.60 (42.96) |
-26.69% | Details | |
| 1/13/2025 | Novo Nordisk | NVO | Maintain | Buy (N/A) |
|
Details | ||
| 9/5/2024 | Novartis | NVS | Downgrade | Neutral (Buy) |
118.50 (155.74) |
31.43% | Details | |
| 7/19/2024 | Novo Nordisk | NVO | Maintain | Buy (N/A) |
|
Details |
